3/30 $RXRXAccum, how long will it take? Funnymentals will determine if/when this will take off. Something something great stonk, moreover better accum pattern
RXRX trade ideas
$42 TARGET $RXRX BUY NOW!The triple bottom chart pattern usually emerges after an extended downtrend with bears dominating the market. While the first bottom might reflect regular price fluctuations, the second bottom signals that the bulls are gathering strength and gearing up for a potential reversal. The third bottom demonstrates robust support, suggesting that bears may surrender when the price surpasses resistance levels.
ALSO: Investing in Recursion Pharmaceuticals (RXRX) offers intriguing possibilities for several reasons:
Innovative Technology: NASDAQ:RXRX utilizes artificial intelligence (AI) and machine learning to expedite drug discovery. Their BioHive-2 supercomputer, powered by Nvidia AI chips, is among the most powerful accelerated computing systems globally.
Partnerships: NASDAQ:RXRX has formed alliances with major tech and healthcare leaders, including Nvidia ( NASDAQ:NVDA ), which invested $50 million into its operations. These collaborations aim to streamline drug discovery, making it faster and more cost-effective.
Promising Pipeline: NASDAQ:RXRX boasts a strong lineup of drug candidates, and their technology has already shown promising results. Their merger with Exscientia, another biotech company focused on AI-driven drug discovery, has created a more robust, vertically integrated platform.
Potential for High Returns: While investing in NASDAQ:RXRX involves risks, it also holds the potential for significant returns. The company's innovative approach could transform the healthcare industry, making it a potential "10-bagger" (a stock that increases tenfold in value).
Long-term Vision: RXRX seeks to shorten the drug discovery process from years to months and significantly reduce costs. This long-term vision could lead to substantial growth if successful.
RXRX SL-$7,45 TP-$9,55Technical Analysis:
Rounded bottom accumulation and compression
Increase in bullish volume
Crossover of EMA 20 and EMA 200
DON'T WALK, RUN!!RXRX is at the heart of AI ADVANCEMENT in biotech. Pioneers in bringing new drugs to market faster and cheaper. One of the largest biological and chemical datasets built for drug discovery and development. Meet BIOHIVE - the world's largest pharmaceutical supercomputer.
Entry (starter position) 8.28 - 9.55
Add on breakout above 9.55
Target: $16-$23 in the coming months.
overshoot: $28-$35 if momentum kicks in hard...
clean chart. all lined up. very nice looking setup.
Not financial advice.
RxRxDefinitely possible to reach 6.90 before earnings... but i think not the likely scenario.
I think the likely scenario is we close above 7.90 for a few days then get a cross followed by some real upward movement.
Any real news that is positive could send this upward at any point now.
I believe 40 - 60 is possible within 3 months if the right media is released along side closing shorts.
Watching all indicators every hour now..
RXRX in a channel between 0.382 fib & golden pocketThere's a channel between the 382 fib and golden pocket on RXRX. I drew 2 trendlines going up and down. It looks like we'll see a continuation of this fib channel but with the possibility of creating new support above the 382 fib line.
Why we played RXRX on Jan 17Good doji set up on the chart
Market was trending upwards, so we wanted to take a risk on a stock and betting in the upward direction.
RXRX Jan 7th 2025GT + FIB + previous high.
Fibonacci Retracement Bounce:
The price is bouncing near the 0.5 Fibonacci retracement level, which is a common support zone in an uptrend. This suggests buyers are stepping in at this level.
Risk-to-Reward Ratio:
The trade setup shows a favorable risk-to-reward ratio (~4:1), with the potential upside significantly larger than the downside.
Bullish Structure:
The price has been making higher highs and higher lows, indicating a clear uptrend on the 4-hour chart.
Consolidation Near Support:
The price appears to be consolidating near a strong support zone (~$7.40), which could act as a launching point for further upward movement.
Breakout Potential:
If the price clears the resistance near $7.80–$8.00, there’s a potential move toward $9.00 and above (a 22% upside as indicated on the chart).
$RXRX - Believe we are at the start of Wave 5I've been trying to wrap my head around the movement with the $9.50 spike recently from an Elliot Wave Theory and fibs perspective. The closest I've gotten to making it all make sense is that we just had a crazy wave 4 correction and this low of $7.24 works out fib wise with wave 1. We also have 4 divergences in our favor.
Let's see how this theory holds!
four bottoms make huge trendThis is a clear long signal with 4 bottoms and long enough flat. As now AI concept changed from hardware to software, there is huge potential up trend, right now.
Stoploss 7.00
daily support level, mean reversion rebounddaily supp level
nvda earnings in AH
price action speaks itself, upside break of trendline and lower vwap band, H&S
mean reversion rebound play with huge potential to be runners if RXRX decide to breakout of its current trading range
bad news overpriced while merger news' full implication on price has yet to be captured
no at bad price to stock up
etc
What do you think?
RXRX long in next couple monthsThis was a request and I want to journal what I got with the dowsing work I do.
I expect this could pop in the short term, but it will likely keep going down.
There may be some support around $4.84, but this is based on the number I get as a percent down, which is 22%. The thing with these numbers though sometimes is that it could also be points, like 2.20 points. But, I'm sticking with the percent for this.
The other thing is that I do get advice as a date, which is October, ugh & I now recognize it's the 22nd. So, that's the number 22 again.
So I try again and get 29th, but I would also keep a heads up for September 29th just in case. I did get the option of an "extreme value buy". So, something could be brewing in the future.
Prescription for Gains!Recursion Pharmaceuticals is building strong bullish momentum, with a gap forming around the $6.00 level. A breakout above the $8.16 resistance would confirm further upside, targeting the $9.99 weekly resistance. This setup provides an attractive risk-to-reward ratio, with downside managed through a stop-loss at $5.49.
In the longer term, RXRX could extend its bullish run to $15.72, supported by the company’s innovative approach to drug discovery using AI and machine learning. As Recursion leverages technology to streamline the development of new therapies, it has positioned itself as a leader in biotech innovation. The increased adoption of AI in healthcare and RXRX’s strategic partnerships further support its potential for strong revenue growth and long-term value.
With both technical momentum and a compelling growth narrative in biotech, RXRX is well-positioned to reach $9.99 in the near term, with an eye on $15.72 as a longer-term target.
NASDAQ:RXRX
RXRX - BIOTECH SQUEEZE PLAY RXRX - Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines.
Consolidating since April, look left and see the explosive moves.
Grab cheap long dated calls and wait for news to come out. Easy R/R. Calls swing 100% on small moves and I've got a good bit cheaply Jan 2025 calls. 9 & 10 dollar strikes.
Huge opportunity here to cash in on any news or favorable Earnings Report in a few days.
Short squeeze targets 10-12 dollars, manage your own risk. Will be dumping calls on impulsive move.
$6 looks to be a strong bottom here, under that for any time other than a flash sale, this trade is invalid, and I won't be holding any calls.
NOT INVESTMENT ADVICE. TRADE YOUR PLAN!
Thanksgiving Gifts for ALL - RXRX - BIOTECH SQUEEZE PLAYRecursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives.
Chart looks primed, bounced off 6 dollar range a few times and is peaking out of the downtrend. I fully expect to find support along that trendline and chop until news sends this thing flying.
Short squeeze potential here and fibs look like a big move could be in store before Thanksgiving which will line up with news around Earnings time.
Holding long dated calls and some shares.
Calls dated Jan 2025 or later. 8,9,10 strikes
Fibs for targets.
LFG!
$RXRX update, bull till Nov 24, the bullishONLY if we reach $5, check 1W PVTO, look at the graph .
Love
Potential Hype Wave...Chart structure looks very good to me and I think there is a chance this goes on a massive hype run this year, Our purple levels marked should not break if this is bullish.
RXRX long ideaExpecting a pre run up into the FDA event.
We are having a gap arround 10.
Lots of recent block buys and kind of a middle high short float.
Recursion Pharmaceuticals, Inc. (RXRX)High-Resolution Genome-Wide Mapping of Chromosome-Arm-Scale Truncations Induced by CRISPR-Cas9 Editing
CRISPR-Cas9 editing is a scalable technology for mapping of biological pathways, but it has been reported to cause a variety of undesired large-scale structural changes to the genome. We performed an arrayed CRISPR-Cas9 scan of the genome in primary human cells, targeting 17,065 genes for knockout with 101,029 guides. High-dimensional phenomics reveals a “proximity bias” in which CRISPR knockouts bear unexpected phenotypic similarity to knockouts of biologically-unrelated genes on the same chromosome arm, recapitulating both canonical genome structure and structural variants. Transcriptomics connects proximity bias to chromosome-arm truncations. Analysis of published large-scale knockout and knockdown experiments confirms that this effect is general across cell types, labs, Cas9 delivery mechanisms, and assay modalities, and suggests proximity bias is caused by DNA double-strand-breaks with cell cycle control in a mediating role. Finally, we demonstrate a simple correction for large-scale CRISPR screens to mitigate this pervasive bias while preserving biological relationships.
$RXRX The artificial intelligence (AI) trade has been blistering higher, but Wednesday featured an interesting surge. That’s as shares of Recursion Pharmaceuticals
RXRX
are exploding higher on the day. In fact, RXRX stock is currently up about 17% so far in the session.
Butterfly with parabolic D leg action.This looks like classic D leg stuff. All parabolic action, few pullbacks and getting a lot of public attention.
PRZ zone tested, I'll take a fade trade off it.
Biotechnology runnersBiotechnology companies develop therapeutics or processes that advance medicine, pharmaceuticals, genomics, food production, and the production of biofuels. Biotech stocks are risky investments, because the development stage of the asset pipeline can take a long time and usually does not even workout in the end. A good example of a long-term successful biotech company is MRNA. But the list of long-term losers is much longer. Here's a top 11 list of Biotechnology runners the past month. 1hr ext chart with the tickerTracker Oscillator set to length 13RSI color coded with it's respective ticker. Can 1 out of 11 of these biotechnology companies become a long-term winner in the future?
IMGN
NERV
NNOX
VYNE
LFCR
CTIC
APYX
MRSN
ICVX
QTRX
RXRX
